Patents Examined by Rachel B Gill
  • Patent number: 11028372
    Abstract: A two-step chromatography purification scheme is described which selectively captures and isolates the genome-containing rAAV vector particles from the clarified, concentrated supernatant of a rAAV production cell culture. The process utilizes an affinity capture method performed at a high salt concentration followed by an anion exchange resin method performed at high pH to provide rAAV vector particles which are substantially free of rAAV intermediates.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: June 8, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Martin Lock, Mauricio Alvira
  • Patent number: 11013797
    Abstract: A method for preventing or treating porcine epidemic diarrhea, the method including: administering a live vaccine of a porcine epidemic diarrhea virus and an adjuvant to a pig through oral administration or nasal administration; and administering an inactivated vaccine of the porcine epidemic diarrhea virus and an adjuvant to the pig through intramuscular administration.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: May 25, 2021
    Assignees: NIPPON INSTITUTE FOR BIOLOGICAL SCIENCE, NISSEIKEN CO., LTD.
    Inventors: Tetsuo Sato, Kazuki Oroku, Yoshiyuki Ohshima, Yoshiaki Furuya, Nobuyuki Tsutsumi
  • Patent number: 11015173
    Abstract: A two-step chromatography purification scheme is described which selectively captures and isolates the genome-containing rAAV vector particles from the clarified, concentrated supernatant of a rAAV production cell culture. The process utilizes an affinity capture method performed at a high salt concentration followed by an anion exchange resin method performed at high pH to provide rAAV vector particles which are substantially free of rAAV intermediates.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: May 25, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Martin Lock, Mauricio Alvira
  • Patent number: 11015174
    Abstract: A two-step chromatography purification scheme is described which selectively captures and isolates the genome-containing rAAV vector particles from the clarified, concentrated supernatant of a rAAV production cell culture. The process utilizes an affinity capture method performed at a high salt concentration followed by an anion exchange resin method performed at high pH to provide rAAV vector particles which are substantially free of rAAV intermediates.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: May 25, 2021
    Assignee: The Trustees of the University of Pennsylvania
    Inventors: Martin Lock, Mauricio Alvira
  • Patent number: 11007265
    Abstract: Disclosed herein is a vaccine comprising an antigen and IL-21. Also disclosed herein are methods for increasing an immune response in a subject. The methods may comprise administering the vaccine to the subject in need thereof.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: May 18, 2021
    Assignees: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, INOVIO PHARMACEUTICALS, INC.
    Inventors: David B. Weiner, Matthew P. Morrow
  • Patent number: 10995121
    Abstract: Human cytomegalovirus vectors comprising heterologous antigens are disclosed. The vectors derived from the TR strain, are ganciclovir-sensitive, include active US2, US3, US6, US7 and UL131A genes, and have a deleterious or inactivating mutation in the UL82 gene preventing the expression of pp71.
    Type: Grant
    Filed: August 20, 2019
    Date of Patent: May 4, 2021
    Assignee: Oregon Health & Science University
    Inventors: Klaus Frueh, Scott G. Hansen, Jay Nelson, Louis Picker, Patrizia Caposio
  • Patent number: 10980874
    Abstract: Recombinant herpes simplex virus 2 (HSV-2) vaccine vectors, virions thereof, compositions and vaccines comprising such, and methods of use thereof are each provided.
    Type: Grant
    Filed: August 18, 2020
    Date of Patent: April 20, 2021
    Assignee: ALBERT EINSTEIN COLLEGE OF MEDICINE
    Inventors: William Jacobs, Jr., Pablo A. Gonzalez-Munoz, Betsy Herold, Christopher Petro
  • Patent number: 10973909
    Abstract: The disclosure relates to polypeptides, vaccines and pharmaceutical compositions that find use in the prevention or treatment of Coronaviridae or SARS-CoV-2 infection. The disclosure also relates to methods of treating or preventing Coronaviridae or SARS-CoV-2 infection in an individual. The polypeptides and vaccines comprise T cell and/or B cell epitopes that are immunogenic in a high percentage of individuals in the human population.
    Type: Grant
    Filed: April 7, 2020
    Date of Patent: April 13, 2021
    Assignee: PepTC Vaccines Limited
    Inventors: Zsolt Csiszovszki, Orsolya Lörincz, Levente Molnár, Péter Páles, Katalin Pántya, Eszter Somogyi, József Tóth, Enikö R. Töke
  • Patent number: 10975168
    Abstract: The present application relates to methods of producing a protein in fucosylated and afucosylated forms at a predetermined ratio.
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: April 13, 2021
    Assignee: GENENTECH, INC.
    Inventors: Shahram Misaghi, John B. Lowe, Bradley Richard Snedecor
  • Patent number: 10973902
    Abstract: The invention is directed to isolated Tilapia Lake Virus or TiLV, and isolated nucleic acids sequences and polypeptides thereof. The invention also relates to probes and primers, and to antibodies against antigens from TiLV, and use of these reagents for detecting the presence or absence of TiLV in an animal. The invention also relates to iRNAs which target nucleic acid sequences of TiLV. The invention is also related to immunogenic compositions, including antibodies and vaccines, for inducing an immune response against TiLV in an animal. The invention is also related to gene constructs and cells comprising TiLV and isolated nucleic acids sequences and polypeptides thereof for use in developing prophylactic and therapeutic agents.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: April 13, 2021
    Assignees: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, RAMOT AT TEL-AVIV UNIVERSITY LTD., KIMRON VETERINARY INSTITUTE
    Inventors: W. Ian Lipkin, Thomas Briese, Nischay Mishra, Eran Bacharach, Avi Eldar
  • Patent number: 10968253
    Abstract: The present invention relates to a virus-derived particle comprising one or more Cas protein(s), as well as to kits and methods using the same for altering a target nucleic acid.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: April 6, 2021
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), ECOLE NORMALE SUPERIEURE DE LYON, UNIVERSITE CLAUDE BERNARD LYON 1
    Inventors: Théophile Ohlmann, Philippe Mangeot, Emiliano Ricci
  • Patent number: 10961504
    Abstract: A method of generating an isolated population of non graft versus host disease (GvHD) inducing cells comprising a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance inducing cells and/or endowed with anti-disease activity, and capable of homing to the lymph nodes following transplantation is disclosed. The method comprising: (a) providing a population of at least 70% memory T cells; (b) contacting the population of memory T cells with an antigen or antigens so as to allow enrichment of antigen reactive cells; and (c) culturing the cells resulting from step (b) in the presence of cytokines so as to allow proliferation of cells comprising the Tcm phenotype. Cells generated by the method, pharmaceutical compositions and methods of treatment are also disclosed.
    Type: Grant
    Filed: June 27, 2017
    Date of Patent: March 30, 2021
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Yair Reisner, Noga Or-Geva, Rotem Gidron Budovsky, Esther Bachar-Lustig, Assaf Lask, Sivan Kagan
  • Patent number: 10961279
    Abstract: The present invention relates to enveloped RNA viruses. The invention in particular relates to the generation of superior antigens for mounting an immune response by first identifying then mutating the immunosuppressive domains in fusion proteins of enveloped RNA viruses resulting in decreased immunosuppressive properties of viral envelope proteins from the viruses.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: March 30, 2021
    Assignee: ISD Immunotech ApS
    Inventors: Mogens Ryttergaard Duch, Shervin Bahrami
  • Patent number: 10946087
    Abstract: The present invention relates to vaccine compositions that are useful in a method of protecting a human subject against dengue disease.
    Type: Grant
    Filed: September 2, 2015
    Date of Patent: March 16, 2021
    Assignee: SANOFI PASTEUR
    Inventors: Nadia Tornieporth, Alain Bouckenooghe, Fernando Noriega, Melanie Saville, Nicholas Jackson, Yves Girerd-Chambaz
  • Patent number: 10925957
    Abstract: Co-administration (for example, immunogenic cocktail compositions and/or prime boost regimens) of computationally optimized H1N1 influenza hemagglutinin (HA) polypeptides is provided. Coadministration of the optimized H1N1 influenza hemagglutinin (HA) polypeptides facilitates synergistic neutralization of viral infection and provides for improved protective immunity (for example, a broad reactive immune response) to diverse and multiple H1N1 influenza virus strains, including both seasonal and pandemic strains.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: February 23, 2021
    Assignees: OREGON HEALTH & SCIENCE UNIVERSITY, SANOFI PASTEUR, INC.
    Inventors: Ted Milburn Ross, Tim Alefantis, Donald Martin Carter, Jr., Christopher Austin Darby, Harold Kleanthous
  • Patent number: 10918712
    Abstract: Methods for passive transfer of immunity using recombinant herpes simplex virus 2 (HSV-2) vaccine vectors, virions thereof, compositions and vaccines comprising such.
    Type: Grant
    Filed: January 3, 2019
    Date of Patent: February 16, 2021
    Assignee: ALBERT EINSTEIN COLLEGE OF MEDICINE
    Inventors: Betsy Herold, William Jacobs, Jr., Pablo A. Gonzalez-Munoz, Christopher Petro
  • Patent number: 10899824
    Abstract: The present invention relates to a combination comprising HSV-1 and HSV-2 binding monoclonal antibodies or fragments thereof and antiviral agents, the pharmaceutical formulations comprising said combination, optionally together with an excipient pharmaceutically acceptable and its use in the prophylaxis and/or treatment of herpes virus infections, including genital herpes, HSV gingivostomatitis and recurrent herpes labialis, herpes simplex encephalitis (HSE), neonatal HSV, HSV disease in the immunocompromised host and HSV keratitis keratoconjunctivitis.
    Type: Grant
    Filed: July 26, 2017
    Date of Patent: January 26, 2021
    Assignee: Polichem S.A.
    Inventors: Roberto Burioni, Massimo Clementi
  • Patent number: 10874734
    Abstract: The present invention relates to a vaccine composition for prevention or treatment of chicken pox or herpes zoster, the vaccine composition comprising a surface protein (gE) of Varicella Zoster Virus and especially an aluminum salt as an adjuvant. The vaccine composition according to the present invention employs a protein antigen, thus showing greater outstanding stability than a live vaccine and has an optimized mixture ratio of adjuvants to elicit effective antibody induction, thereby being useful as a vaccine for preventing or treating Varicella Zoster Virus-caused chicken pox or herpes zoster.
    Type: Grant
    Filed: November 24, 2017
    Date of Patent: December 29, 2020
    Assignee: MOGAM INSTITUTE FOR BIOMEDICAL RESEARCH
    Inventors: Hyo Jung Nam, Eunmi Kim, Gayoung Ji
  • Patent number: 10869919
    Abstract: A porcine circovirus type 3 virus strain and a vaccine composition prepared from the immunogenic substance of the strain are described. The porcine circovirus type 3 virus strain has good immunogenicity, and the prepared vaccine composition can provide complete protection against varies of porcine circovirus type 3 viruses from different sources.
    Type: Grant
    Filed: November 30, 2017
    Date of Patent: December 22, 2020
    Assignee: PULIKE BIOLOGICAL ENGINEERING, INC.
    Inventors: Kegong Tian, Xiangdong Li, Yan Xiao, Jinzhong Sun, Xuke Zhang
  • Patent number: 10864263
    Abstract: Provided are methods for generating an immune response against a Zika virus in a human subject in need thereof. The methods comprise administering to the subject a pharmaceutical composition comprising adenoviral vectors encoding a Zika virus antigen and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: December 15, 2020
    Assignees: Janssen Pharmaceuticals, Inc., Beth Israel Deaconess Medical Center. Inc.
    Inventors: Dan Barouch, Macaya Julie Douoguih, Gaston Rafael Picchio